EPS for Curis, Inc. (CRIS) Expected At $-0.41

July 11, 2018 - By Michele Cranor

Curis, Inc. (NASDAQ:CRIS) LogoInvestors sentiment decreased to 0.86 in Q1 2018. Its down 0.73, from 1.59 in 2017Q4. It turned negative, as 10 investors sold Curis, Inc. shares while 25 reduced holdings. 14 funds opened positions while 16 raised stakes. 62.11 million shares or 17.79% less from 75.55 million shares in 2017Q4 were reported.
Vanguard Group has invested 0% in Curis, Inc. (NASDAQ:CRIS). Citadel Advisors Ltd Co owns 0% invested in Curis, Inc. (NASDAQ:CRIS) for 14,532 shares. Mackenzie Financial Corp has invested 0% in Curis, Inc. (NASDAQ:CRIS). American Century Inc holds 0% or 12,996 shares in its portfolio. Walleye Trading Limited Liability has invested 0% in Curis, Inc. (NASDAQ:CRIS). Invesco owns 10,446 shares or 0% of their US portfolio. Renaissance Techs Lc invested in 0% or 3.95M shares. Jpmorgan Chase & holds 0% in Curis, Inc. (NASDAQ:CRIS) or 26,623 shares. 184,490 were reported by Focused Wealth Mngmt. Citigroup accumulated 17,529 shares. Grp One Trading L P reported 12,167 shares. 8,000 were reported by Northwestern Mutual Wealth Mngmt Company. Principal Grp reported 17,990 shares. D E Shaw Company Incorporated accumulated 0% or 827,783 shares. 906 were reported by Daiwa Group Incorporated.

Analysts expect Curis, Inc. (NASDAQ:CRIS) to report $-0.41 EPS on August, 2.They anticipate $0.09 EPS change or 18.00 % from last quarter’s $-0.5 EPS. After having $-0.35 EPS previously, Curis, Inc.’s analysts see 17.14 % EPS growth. The stock increased 3.37% or $0.06 during the last trading session, reaching $1.84. About 143,273 shares traded. Curis, Inc. (NASDAQ:CRIS) has declined 73.52% since July 12, 2017 and is downtrending. It has underperformed by 86.09% the S&P500.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Among 2 analysts covering Curis (NASDAQ:CRIS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Curis had 2 analyst reports since May 7, 2018 according to SRatingsIntel. Robert W. Baird maintained the stock with “Outperform” rating in Monday, May 7 report. The stock has “Buy” rating by SunTrust on Thursday, May 31.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $60.95 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

More recent Curis, Inc. (NASDAQ:CRIS) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” on June 29, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Titan’s Parkinson’s Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32 …” with publication date: July 03, 2018 was also an interesting one.

Curis, Inc. (NASDAQ:CRIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.